Ligand Pharmaceuticals financials
$310.36−1.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M | $241.5M | $163.6M | $120.3M | $251.5M | $141.1M | $109.0M |
| Gross profit | $253.5M | $156.1M | $120.8M | $143.4M | $179.4M | $133.1M | $108.9M | $245.1M | $135.7M | $103.4M |
| Gross margin | 94.6% | 93.4% | 92.0% | 73.1% | 74.3% | 81.4% | 90.6% | 97.5% | 96.2% | 94.9% |
| Operating income | $41.0M | -$7.6M | $9.8M | $3.0M | $103.9M | $20.4M | -$5.7M | $163.7M | $68.1M | $43.9M |
| Net income | $124.5M | -$4.0M | $52.2M | -$33.4M | $57.1M | -$3.0M | $629.3M | $143.3M | $12.6M | -$1.6M |
| Net margin | 46.4% | −2.4% | 39.7% | −17.0% | 23.7% | −1.8% | 523.2% | 57.0% | 8.9% | −1.5% |
| Diluted EPS | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 | $-0.18 | $31.85 | $5.96 | $0.53 | $-0.08 |
| EBITDA | $81.0M | $58.3M | $46.3M | $54.6M | $154.8M | $48.4M | $38.0M | $178.4M | $79.8M | $55.2M |
| Operating cash flow | $49.4M | $97.0M | $49.6M | $137.8M | $78.8M | $54.6M | -$29.3M | $198.0M | $88.8M | $61.0M |
| Free cash flow | $48.9M | $95.2M | $46.1M | $119.9M | $70.0M | $50.1M | -$31.9M | $197.1M | $86.6M | $59.2M |
| Diluted shares | 20.3M | 18.3M | 17.8M | 16.9M | 17.2M | 16.8M | 19.8M | 24.1M | 23.5M | 20.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $174.9M | $72.3M | $23.0M | $45.0M | $19.5M | $47.6M |
| Short-term investments | $581.4M | $183.9M | $147.4M | $166.9M | $321.6M | $363.6M |
| Total debt | $446.2M | $0.00 | $7.0K | $76.7M | $320.8M | $448.9M |
| Total assets | $1.56B | $941.8M | $787.2M | $762.7M | $1.30B | $1.36B |
| Total liabilities | $543.4M | $111.3M | $86.3M | $165.2M | $476.4M | $652.8M |
| Shareholders' equity | $1.02B | $830.4M | $700.9M | $597.5M | $821.2M | $709.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology